Journal article
Multisystem immune-related adverse events from dual agent immunotherapy use.
Abstract
2635
                  Background: Immune-related adverse events (irAEs) are commonly seen in cancer patients who undergo immunotherapy treatment. Increasingly, there has been recognition that multiple different irAEs can occur during or/and after a single course of immunotherapy treatment, known as multisystem irAEs, though much remains unknown. The primary objective of this study was to assess for rate of multisystem irAEs in patients who …
Authors
Li Y; Pond GR; McWhirter E
Journal
Journal of Clinical Oncology, Vol. 41, No. 16_suppl, pp. 2635–2635
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2023
DOI
10.1200/jco.2023.41.16_suppl.2635
ISSN
0732-183X